Related Experiment Video
Updated: Nov 10, 2025
Quantifying the Antifungal Activity of Peptides Against Candida albicans
Published on: January 13, 2023
Fungicidal Activity of a Safe 1,3,4-Oxadiazole Derivative Against Candida albicans
Daniella Renata Faria1, Raquel Cabral Melo1, Glaucia Sayuri Arita1
1Laboratory of Medical Mycology, Department of Clinical Analysis and Biomedicine, State University of Maringá (UEM), Maringá, Paraná 87020-900, Brazil.
Abstract:
Candida albicans is the most common species isolated from nosocomial bloodstream infections. Due to limited therapeutic arsenal and increase of drug resistance, there is an urgent need for new antifungals. Therefore, the antifungal activity against C. albicans and in vivo toxicity of a 1,3,4-oxadiazole compound (LMM6) was evaluated. This compound was selected by in silico approach based on chemical similarity. LMM6 was highly effective against several clinical C. albicans isolates, with minimum inhibitory concentration values ranging from 8 to 32 µg/mL. This compound also showed synergic effect with amphotericin B and caspofungin. In addition, quantitative assay showed that LMM6 exhibited a fungicidal profile and a promising anti-biofilm activity, pointing to its therapeutic potential. The evaluation of acute toxicity indicated that LMM6 is safe for preclinical trials. No mortality and no alterations in the investigated parameters were observed. In addition, no substantial alteration was found in Hippocratic screening, biochemical or hematological analyzes. LMM6 (5 mg/kg twice a day) was able to reduce both spleen and kidneys fungal burden and further, promoted the suppresses of inflammatory cytokines, resulting in infection control. These preclinical findings support future application of LMM6 as potential antifungal in the treatment of invasive candidiasis.
Insights
A novel compound, LMM6, shows potent antifungal activity against Candida albicans, a common cause of hospital infections. Preclinical studies demonstrate its safety and efficacy in controlling candidiasis, suggesting its potential as a new antifungal treatment.
Area of Science:
- Mycology
- Medicinal Chemistry
- Infectious Diseases
Background:
- Candida albicans is a leading cause of nosocomial bloodstream infections.
- Limited antifungal options and increasing drug resistance necessitate new therapeutic agents.
- In silico screening identified 1,3,4-oxadiazole compound LMM6 for evaluation.
Purpose of the Study:
- To evaluate the antifungal activity of LMM6 against Candida albicans.
- To assess the in vivo toxicity and therapeutic potential of LMM6.
- To investigate LMM6's efficacy in a preclinical model of invasive candidiasis.
Main Methods:
- Antifungal susceptibility testing (MIC) against clinical C. albicans isolates.
- Synergy testing with existing antifungals (amphotericin B, caspofungin).
- In vitro fungicidal and anti-biofilm assays.
- Acute toxicity and preclinical in vivo studies in a murine model.
Main Results:
- LMM6 demonstrated high efficacy against C. albicans (MIC 8-32 µg/mL).
- Synergistic effects observed with amphotericin B and caspofungin.
- LMM6 exhibited fungicidal and anti-biofilm properties.
- No significant toxicity observed in acute and preclinical studies.
- LMM6 treatment reduced fungal burden and suppressed inflammatory cytokines in vivo.
Conclusions:
- LMM6 is a potent antifungal agent with a promising safety profile.
- LMM6 demonstrates therapeutic potential for treating invasive candidiasis.
- Further preclinical development of LMM6 is warranted.
